VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

04 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

27 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

22 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

21 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

10 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

09 ноя 2023 16:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

06 ноя 2023 16:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

09 окт 2023 16:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

30 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

10 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023

03 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

02 авг 2023 16:06:38 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

14 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

07 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

31 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

11 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

04 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

24 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

23 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire